Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18246158 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18246529 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18247250 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL21748033 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18246554 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL29219033 | 1.00 | APLNR (1.00) | APLNR | |
| SCHEMBL18492882 | 0.95 | APLNR (1.00) | APLNR | |
| SCHEMBL18246358 | 0.95 | APLNR (1.00) | APLNR | |
| SCHEMBL18246921 | 0.95 | APLNR (1.00) | APLNR | |
| SCHEMBL21097425 | 0.94 | APLNR (1.00) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646220-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | Bioage Labs, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4593815-A1 | APELIN RECEPTOR AGONISTS FOR TREATING MUSCLE CONDITIONS | Bioage Labs, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4532015-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | Bioage Labs, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119546323-A | Apelin peptide receptor modulators for the treatment of disorders or diseases related to BBB permeability | 百爱及生物医药公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. | 2024-11-07 | — | — | US | disclosed |
| WO-2024148104-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | BioAge Labs, Inc. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-117897157-A | Apelin receptor modulators for the treatment of age-related muscle disorders | 百爱及生物医药公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2024072907-A1 | APELIN RECEPTOR AGONISTS FOR TREATING MUSCLE CONDITIONS | BioAge Labs, Inc. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-4319873-A1 | APELIN RECEPTOR MODULATORS FOR TREATING AGE-RELATED MUSCLE CONDITIONS | Bioage Labs, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023235360-A1 | APELIN RECEPTOR MODULATORS FOR TREATMENT OF A DISORDER OR DISEASE ASSOCIATED WITH BBB PERMEABILITY | BioAge Labs, Inc. (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2022216871-A1 | APELIN RECEPTOR MODULATORS FOR TREATING AGE-RELATED MUSCLE CONDITIONS | BioAge Labs, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366602-A1 | COMBINATION THERAPY OF APELIN RECEPTOR AGONIST AND GLP-1 RECEPTOR AGONIST FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH WEIGHT GAIN | APLNR, GLP1R, GIPR | APLNR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.